The Hypertension Optimal Treatment in Children with Chronic Kidney Disease study: the HOT-KID study - a randomised trial to compare effects of aggressive versus standard targets in blood pressure on target organ damage in children with CKD

Guy's and St. Thomas' NHS Foundation Trust (UK)0 个研究点目标入组 124 人开始时间: 2012年8月16日最近更新: 2023年1月9日

适应症

试验速览

•1. Aged 2 to 15 years
•2. Chronic kidney disease with eGFR between 15-90 ml/min/1.73m2 for two consecutive measurements in the last 12 months
•3. With or without anti-hypertensive/s medications (irrespective of recent change/s in antihypertensive therapy)
•4. Subjects with average clinic systolic BP <50th percentile and on no antihypertensive medication will be eligible as ?CONTROL? subjects only
•5. Other ?CONTROL? subjects will include children with normal renal function and blood pressure attending hospital for unrelated medical review or siblings of subjects with CKD
•6. Male and female participants

•1. Age <2 and >15 years
•2. Subjects who have/had an arterio-venous fistulae
•3. Subjects who have/had are on dialysis
•4. Subjects who have/had a functioning kidney transplant
•5. Patients with symptomatic BP or with past history of difficulty to control BP or
•6. Patients in whom there is a clinical urgency to treat BP and inclusion in study may result inpossible delay of treatment
•7. Patients with arrhythmia or clinical heart failure
•8. Patients with known structural cardiac abnormality
•9. Subjects on treatment with angiotensin converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB) agents for treatment of proteinuria only or
•10. Subjects who are likely to be of clinical concern following up or down titration of BP levels as described in ?Appendix 3?
•11. Subjects who are unable or intolerant to performance of study measurements e.g. height, echo or PWV
•12. Subjects who have/had intolerance to Angiotensin converting enzyme inhibitors (ACEi) drug/s or have any existing contraindications

发起方

Guy's and St. Thomas' NHS Foundation Trust (UK)